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Introduction: 
This article is a review of the highlights of pertinent literature published during the 12 months of 2017, 
which is of interest to the congenital cardiac anesthesiologist. Following a search of the US National 
Library of Medicine PubMed database, several topics emerged where significant contributions were made 
in 2017, and that the authors of this manuscript felt were noteworthy to be summarized in this review: 
Training in pediatric cardiac anesthesia, the costs of congenital heart disease (CHD), catheter versus 
surgical intervention for CHD, cerebral oxygen saturation in CHD, and mechanical circulatory support in 
children.  
 
Training in pediatric cardiac anesthesia 
In 2004, the Accreditation Council for Graduate Medical Education (ACGME) Next Accreditation system 
was implemented with the creation of milestones to all specialties.(1) Since 2007, for surgeons who 
operate on patients with CHD ranging from neonates to adults, a subspecialty certification in congenital 
cardiac surgery is granted following completion of a one-year accredited residency and passing of a 
written examination and an oral examination.(2) The number of accredited surgical programs in the US 
has increased from 2 in 2006 to 12, and the number of graduates has increased from 2 in 2008 to 44 in 
2014.(3,4) Along with the increase in structured training for congenital cardiac surgery, there has been an 
increase in the need of physicians with advanced knowledge and experience in pediatric cardiac intensive 
care. Several informal advanced training pathways have been suggested following surgical, anesthesia or 
intensive care trainings and were discussed at the 10
th
 International Conference of the Pediatric Cardiac 
Intensive Care Society.(5) Similarly to surgical and intensive care specialties, pediatric cardiac 
anesthesiology has evolved as a subspecialty devoted to patients with CHD ranging from neonates to 
adults. While there is a consensus on the need to define standards for the pediatric cardiac anesthesia 
fellowship, there remains a wide variability in duration of training and clinical experience. Different 
training pathways have been proposed in the past few years and several recent publications are 
highlighted to outline the proposed future pathways.  
In Germany, a working group representing the German Society for Anesthesiology and Intensive Care 
surveyed all pediatric cardiac centers with the intent to define “expertise in pediatric cardiac 
anesthesia”.(6) Twenty-seven centers with an active pediatric cardiac surgery program participated in the 
survey with a response rate of 96.3%.  The suggested length of training in pediatric cardiac anesthesia 
was 12-months in 42.3% of centers with a mean of 10.8-months to achieve sufficient experience. 
However, the length of training may not be reflective of the competence of the trainee.(7) Because, 
different learners with different knowledge or experience backgrounds progress at different rates, the time 
needed by a trainee to achieve competence may vary.(8,9) Recently, based on the ACGME Milestones 
Model and recognizing that the duration of training does not reflect competency, an expert panel of the 
Congenital Cardiac Anesthesia Society, a section of the Society of Pediatric Anesthesia defined 18-
milestones as competency-based developmental outcomes for the pediatric cardiac anesthesia 
fellowship.(10) These 18 milestones cover all six-core competencies of the ACGME including patient 
care, medical knowledge, systems-based practice, practice based learning and improvement, 
professionalism, and interpersonal and communication skills. They are listed in details in Table 1. In 
addition, recognizing the increase in adult patients with CHD and adult congenital heart centers as 
described by Kogon et al., these milestones address competency in anesthesiology for patients with CHD 
across the age spectrum from neonates to adults.(11) Pediatric cardiac anesthesiology is defined in the 
Consensus Statement as a subspecialty “devoted to caring for individuals with congenital heart disease 
ranging in age from neonates to adults.” (10) Currently there are 17 programs in the US that offer 24 
positions for pediatric cardiac anesthesia fellowship.(12) Each of these programs as well as international 
programs can use the recently described milestones as a template to define the objectives of the 
fellowship and develop a milestone-based curriculum.  
 
The Cost of CHD 
Adults living with CHD now outnumber children with CHD. In both children and adults, hospital 
admissions and associated costs may be the result of their primary CHD, or associated cardiac and non-
cardiac comorbidities. Frequently, repair of a specific CHD requires multiple admissions (i.e. staged 
single ventricle palliation), or revisions later in life. Readmission rate after surgery is high, further 
increasing healthcare resource use and costs. It is obvious that the healthcare environment is undergoing 
major changes. Payers are increasingly reluctant to reimburse for quantity, and metrics of efficiency and 
quality are being established as the basis of reimbursement. It is therefore increasingly important to 
understand what drives costs in CHD. In 2017 several noteworthy contributions were made that help 
practitioners and administrators alike, to better understand the costs associated with CHD. 
For example, Mackie and colleagues conducted a retrospective cohort study using the Canadian Institute 
for Health Information Discharge Abstract Database between 2004 and 2014.(13) Among 59,917 
hospitalizations that included CHD as the primary or related diagnosis they found a 21.6% increase in 
costs over the ten-year study period. Costs were higher for children compared with adults; however, the 
cost increase was greater in adults (4.5%/year) than in children (0.7%/year). Costs increased the most 
among adults with complex CHD (7.2%/year). The study investigators conclude that although children 
still account for greater inpatient CHD costs, adults with CHD are increasingly contributing to the overall 
cost burden of CHD on healthcare resources. Although the length of stay over the observed time period 
was unchanged in this study, it is without question that length of hospital stay is a major driver of 
inpatient hospital costs. Cedars and colleagues analyzed multiple State Inpatient Databases identifying 
99,103 inpatient hospitalizations in adults with CHD.(14) They found that overall the variables most 
strongly associated with increased length of stay, regardless of underlying CHD anatomy, were acute 
renal failure, bacterial infection, complications from medical or surgical procedures and anemia. These 
potentially modifiable risk factors could be used to design targeted interventions to decrease length of 
stay and potentially cost in adult CHD inpatient care. 
While many adult CHD hospitalizations are due to cardiac complications, there are a substantial 
proportion of admissions due to non-cardiac morbidities that are increasing as the population of adults 
with CHD ages. Seckeler and colleagues studied the cost of hospitalization for non-cardiac disease for 
adults with CHD.(15) They conducted a retrospective review of hospital discharge data from the 
University Health System Consortium Clinical Database from 2011 to 2013. They compared 9,169,700 
adults without CHD to adults with differing severities of CHD. This study identified significantly 
increased hospitalization costs for adults with moderate and complex CHD who are admitted for non-
cardiac medical conditions. Admissions with CHD diagnoses had higher ICU admission rates, longer 
lengths of stay, and higher mortality for most non-cardiac admission diagnoses. The study investigators 
point out that the creation of adult CHD centers of excellence in Quebec, Canada are associated with a 
decrease in all-cause mortality and cost in this patient population.(16) There may be a role for 
regionalization of adult CHD care in the USA as well, allowing highly specialized providers to focus on 
the general health and non-cardiac comorbidities that patients will experience as they age. 
The presence of non-cardiac comorbidities is not unique to adult patients. Tuomela and colleagues studied 
non-cardiac comorbidities in infants with CHD and the impact on resource utilization.(17) They found 
non-cardiac comorbidities occurred in 55% of infants. Most commonly observed were gastrointestinal 
(the need for enteral tube feeds, malrotation), respiratory (vocal cord dysfunction, airway malacia) and 
genetic diseases (Trisomy 21 and DiGeorge syndrome). The Society of Thoracic Surgeons-European 
Association for Cardio-Thoracic Surgery (STAT) score and the presence of multiple comorbidities were 
associated with higher resource utilization following the index cardiac surgical procedure. 
Although the association between genetic abnormalities and CHD is well known, its combined impact on 
resource use and cost has not been evaluated. Furlong-Dillard and colleagues studied the resource use and 
morbidities in infants with CHD and genetic conditions.(18) Using the Pediatric Health Information 
System Database, they identified 95,253 children under the age of 18 years undergoing congenital heart 
surgery. Of these, 84.6% had no genetic condition, trisomy 21 (9.9%), trisomy 13 or 18 (0.2%), DiGeorge 
syndrome (0.8%), Turner syndrome (0.4%) and ‘other’ genetic conditions (4.2%). Although 
complications varied by genetic condition, all groups with genetic abnormalities experienced increased 
length of stay and cost. Identifying genetic abnormalities in patients with CHD may thus, be helpful in 
deciding which children might benefit from a cardiac complex care program that partners families and 
providers to improve health and decrease healthcare costs. As an example Geddes and colleagues showed 
that implementing a standardized protocol with the help of a geneticist, increased the rate of diagnosis of 
genetic conditions and reduced cost per diagnosis significantly.(19)   
Another important factor driving costs in CHD is hospital readmission rate, which is increasingly 
becoming a metric for quality in the current landscape of cost-effective medicine. Payers are viewing 
readmissions as preventable, often denying reimbursement for these hospitalizations. However, it is clear 
that infants with CHD are often readmitted to the hospital for both further planned procedures and 
unplanned reasons. In an Australian study the rate of cardiac surgical procedures in the first year of life 
was steady at 2.5 children per 1000 live births.(20) Excluding infants who had ligation of a patent ductus 
arteriosus, 50% required readmission in the first year of life and over 20% of these infants had an 
additional non-cardiac congenital anomaly. Similarly, Sacks et al found a 20.5% readmission rate for 
infants with CHD not requiring surgery in a USA based study of 30-day readmission rates.(21) Patient 
factors associated with an increased likelihood of 30-day readmission were younger age, lower discharge 
weight and greater number of diagnoses and a longer length of initial stay. These results indicate that 
many common factors associated with readmissions are not easily modifiable. However, factors 
associated with readmissions may serve as important prognostic indicators, and a basis for counseling and 
potential cost savings. 
Single ventricle pathology is perhaps the most complex form of CHD and increasing numbers of children 
with this condition now survive to adulthood. The single ventricle palliation pathway is associated with 
significant resource use and costs, as can be seen in a recent study by Huang and colleagues who studied 
156 patients from the Fontan Registry Database in Australia and New Zealand, from birth to Fontan 
completion.(22) During the staged surgical treatment period, children had a mean 10 +/- 6 inpatient 
admissions and spent 85 +/- 64 days in hospital. Although cardiac surgeries were the major reason for 
resource use (77% of the total cost), non-cardiac admission costs were 18% of the total costs. Costs were 
higher in male and HLHS patients in the staged procedures period. Interestingly, over 40% of the 
pediatric hospital costs for Fontan patients occurred after the last planned surgery.(23)  
Aside from a change in demographics (i.e. increasing number of adults with CHD), associated 
comorbidities and frequent readmissions, all contributing to the significant costs associated with CHD, 
care for CHD patients by itself is often more costly compared to other cardiac surgery populations. In a 
study using the 2013 Nationwide Inpatient Sample Database, Nasr and colleagues compared costs and 
outcomes for adult patients undergoing surgery for treatment of CHD to a reference population of adults 
undergoing coronary artery bypass graft (CABG).(24) This study showed that adult CHD patients 
undergoing cardiac surgery experience higher hospital costs and poorer outcomes than the reference 
population of adult CABG patients. Variation in the clinical management of patients with CHD may be 
partially responsible. For example the off-label use of iNO is common in children undergoing cardiac 
surgery but the efficacy is unclear and the cost substantial. Gupta and colleagues studied the use of iNO 
after pediatric cardiac surgery, among centers of varying surgical volume.(25) Using the Pediatric Health 
Information System database, Gupta and colleagues identified 103,714 children from 41 hospitals of 
which 15.1% received iNO after cardiac surgery. They found higher iNO utilization among centers with 
lower surgical volume which also had worse outcomes (including mortality) compared to centers with 
higher surgical volume. There was wide variation in iNO utilization among centers and only 25% patients 
receiving iNO had an associated diagnosis of pulmonary hypertension. This may indicate that current 
indications for the use of iNO are poorly defined and/or poorly implemented and its arbitrary use 
significantly increases post-operative costs. There is clearly an opportunity to introduce a standardized 
protocol for the post-operative use of iNO to help guide clinical decisions and reduce costs. Rathod and 
colleagues undertook an excellent study in which they implement Standardized Clinical Assessment and 
Management Plans (SCAMPs) in children after the arterial switch operation (ASO).(26) Patient 
management that included SCAMPs resulted in significantly lower resource use and overall costs, and no 
difference in clinical outcomes between the historical and SCAMP cohorts. This study indicates that 
SCAMPs may be an excellent way forward for many institutions to improve resource utilization and 
reduce costs not only in ASO patients, while maintaining quality of care. 
 
Catheter versus surgical intervention for CHD 
In 1953 Rubio-Alvarez and colleagues reported the first successful cardiac catheter-based interventional 
technique for treatment of a congenital cardiac defect when they described cutting across a stenotic 
pulmonary valve using a “bow string” apparatus deployed at the catheter tip.(27) Little notice was taken, 
and it was more than a decade later that Rashkind and colleagues reported their results using balloon atrial 
septostomy to allow mixing of oxygenated and deoxygenated blood in cyanotic defects.(28) This was to 
become the first widely-used non-surgical technique for palliation of CHD, and it is still in use today.  
Since that time, catheter-based interventions for treatment of CHD have become increasingly 
sophisticated and wide-spread.  Indeed, with the increased utility of echocardiography and cardiac MRI as 
diagnostic techniques, the congenital cardiac catheterization laboratory has become more of a treatment 
center and less of a strictly diagnostic tool.   
Current catheter-based interventional techniques are progressively expanding. Theoretical advantages of 
catheter-based interventional techniques over surgery are numerous and include absence of a surgical 
incision, avoidance of the effects of cardiopulmonary bypass, reduced infection rate, less pain, shorter 
procedure time, faster recovery time, and lower cost.  At the same time, catheter-based interventions are 
not without risk.  The Congenital Cardiac Interventional Study Consortium recently developed the 
Catheterization RISk Score for Pediatrics (CRISP) based on pre-intervention variables.  The authors 
identified 41 reported significant adverse events (SAEs) in their study population involving 14,790 
catheter-based interventional procedures. Many of these SAEs were specifically related to the 
interventional procedure, such as device migration, stent malposition, and wire retention.(29)  Despite the 
expanding use of catheter-based interventional techniques in the management of CHD, important 
questions remain regarding their advantages over conventional surgery.   
Several studies in 2017 analyzed the outcomes of both interventional and surgical treatment of various 
congenital heart lesions.  Glatz and colleagues looked at the use of PDA stents versus modified Blalock-
Taussig shunt (BTS) in patients with ductal-dependent pulmonary blood flow.(30) This was a multicenter 
comparison study by the Congenital Catheterization Research Collaborative, which includes investigators 
from four institutions.  Patients were treated with either BTS or catheter-based PDA stent placement in all 
centers.  There was no statistically significant difference in the composite primary outcome of death or re-
intervention to treat cyanosis between the two groups, and the PDA stent group compared favorably in 
several secondary outcomes.  For example, the PDA stent group had a lower ICU length of stay (5.3 vs. 
9.19 days), was less likely to be on diuretics at discharge, and had fewer procedural complications (when 
adjusted for patient factors).  When the PDA stent group returned later for either follow-up or definitive 
surgical repair, they were found to have larger and more symmetric pulmonary arteries (PAs).  This was 
postulated to be the result of a shunt source that was (1) central (rather than to a branch pulmonary 
artery), and (2) not associated with anastomotic vessel distortion (which is often seen with BTS).  Perhaps 
as a result of this, the PDA stent group also tended to present for definitive surgery at an older age and 
after a longer interval since initial palliation (stent placement or BTS).  However, the BTS group was no 
more likely to require pulmonary arterioplasty at the time of definitive surgical repair, nor did they 
require more subsequent PA interventions.  In contrast, the PDA stent group did require more overall re-
interventions, such as re-dilation of the stent by balloon angioplasty or pulmonary valvuloplasty.  This 
likely reflects the unique nature of interventional stent placement and the opportunity to re-intervene 
through catheter-based techniques.  Although catheter-based interventions present unique challenges, this 
first-of-its-kind large multicenter comparison indicates that PDA stent placement is a viable option versus 
BTS for patients with ductal-dependent lesions. 
One lesion that has historically been palliated with BTS is Tetralogy of Fallot (TOF) associated with early 
severe cyanosis and/or ductal dependence.  The Glatz study did not include TOF among the anatomic 
diagnoses of its subjects, perhaps because several major centers have moved away from this strategy, 
instead favoring either early complete repair or catheter-based palliation.  An example is the Hospital for 
Sick Children in Toronto, where Wilder and colleagues recently reported the outcomes from their 
institution using either early (<3 months of age) primary repair (the EARLY group) or catheter-based 
palliation (the CATH group).  Interventions used in the CATH group included right ventricular outflow 
tract stent, ductal stent, and right ventricular outflow tract balloon angioplasty.  Patients who did not 
require early intervention but instead underwent elective repair after 3 months of age (the IDEAL group) 
served as a control group.(31)  All three strategies (EARLY, CATH, and IDEAL) were associated with a 
low mortality rate, with 1 death in each group.  The re-intervention rate was higher in the CATH group 
compared to the others, and the risk of reoperation was higher in the EARLY group.  However, long-term 
outcomes including survival, somatic growth, right ventricular systolic pressure, branch pulmonary artery 
dimensions, and prevalence of pulmonary insufficiency were not significantly different among groups at 
8-10 year follow up.  One limitation of this study is the selection bias inherent in a single-institution 
analysis – patients in the CATH group were more likely to be selected for catheter-based intervention if 
they were deemed less likely to tolerate early complete surgical repair based on systemic disease.  Risk-
adjustment was used to limit the impact of such patient-specific differences, but even if this was flawed 
by the relatively low patient numbers in the study the bias would tend to be unfavorable toward the 
outcomes in the CATH group.  Despite this, the CATH group compared favorably to both the EARLY 
and IDEAL groups in the long term. 
Recurrent coarctation of the aorta is a common problem after the Norwood operation for palliation of 
single ventricle lesions.  Treatment options include surgical re-operation, balloon angioplasty, or catheter-
based stent implantation at the coarctation site.  Redo surgery is associated with good long-term results, 
but it entails the risks associated with repeat sternotomy and cardiopulmonary bypass.  While balloon 
angioplasty has been commonly employed, it may not be effective for all lesions and is associated with a 
fairly high re-stenosis/re-intervention rate.(32)  Theoretically, placing a stent at the coarctation site should 
provide a longer-term solution compared to ballooning alone.  This was studied by Aldoss and colleagues, 
who reviewed outcomes for stent implantation for recurrent coarctation in the Norwood population in 33 
patients at 8 centers.(33) The authors report excellent immediate results of both improvement of the aortic 
diameter and reduction in the coarctation pressure gradient with stenting.  Twelve patients (36%) had 
SAEs.  No patients died or required mechanical support.  It was noted that a prograde catheter approach 
(percutaneous venous access with catheter course across the tricuspid and neo-aortic valves) was more 
commonly associated with hemodynamic compromise than a retrograde or other approach, likely related 
to iatrogenic insufficiency of one or both valves.   Despite the good early results, over half the patients did 
require re-intervention to balloon the stent.  Half of these were simply the result of somatic growth, but 
half were due to in-stent stenosis, residual arch obstruction, or stent fracture. The authors speculate that 
future stents may be bioabsorbable, creating an option that would less likely require re-intervention, as the 
stent would absorb quickly enough to allow somatic vessel growth. 
Another lesion that has long been managed with catheter-based intervention is persistent PDA.  
Traditionally, catheter-based intervention using coils or occluders has been undertaken mostly in children 
and adults, with limited application in infants < 1 year of age.  This leaves open questions about the 
feasibility, safety and efficacy of this technique compared to surgical closure in infants.  Backes and 
colleagues conducted a meta-analysis of the existing literature to investigate the technical success and 
safety of percutaneous PDA closure during infancy.(34)  Thirty-eight studies representing 635 infants 
were included. Technical success, defined as the infant leaving the cath lab with a coil or device in the 
PDA, was high (92.2%).  Procedural abandonment occurred in 40 patients, most commonly related to 
either device malposition or an adverse event (AE).  If residual ductal shunting was observed following 
the procedure, it usually resolved within 24 hours, with only 8 cases reported as remaining patent at 
longest follow-up (3-36 months).  The SAE rate was about 10%, with major or catastrophic events 
occurring in 1.6%.  Over 92% of major or catastrophic events occurred among infants <6 kg.  At least one 
death was reported; this was related to a cardiac perforation in a 1.5 kg premature infant.  Publication 
bias, measured by the LFK index, was considered “major” (LFK index exceeds 2) in many of the 
articles reviewed, indicating a tendency to report only clinically significant findings.  This, and the void 
of randomized controlled trials investigating this technique, makes it difficult to draw conclusions about 
the superiority of this technique to surgery in the neonatal population.  However, the preponderance of the 
available evidence would indicate that percutaneous PDA closure in the infant population is feasible and 
relatively safe, with few major or catastrophic adverse events (especially among infants >6 kg). 
 
 
 
Cerebral oxygen saturation in CHD. 
Near infrared spectroscopy (NIRS) is a non-invasive optical technology for measurement of tissue 
oxygenation. Commercialization of NIRS led to the development of tissue oximeters, which allow for 
continuous bedside monitoring of cerebral (ScO2) and somatic (StO2) tissue oxygen saturation.(35) The 
premise for cerebral oximetry is the identification of cerebral hypoxia, or hyperoxia (especially in 
premature neonates) to help guide therapy and improve clinical outcomes.(36, 37)  
Treatment algorithms have been devised to guide practitioners in treating possible causes of cerebral 
desaturation or hyperoxia.(38)  Interventions are triggered either by trend monitoring and deviation from 
baseline values, or absolute lower and upper thresholds beyond which the possibility for cerebral injury 
may increase. Establishing a normal range for ScO2 in both pediatric and adult populations is therefore 
clinically important, but is beset with problems (beyond the scope of this article). In healthy children the 
normal range for ScO2 is a mean (±SD) of 68% ± 10%.(39) However, what constitutes normal values in 
the diverse group of CHD patients has mostly been speculative and based on small population 
samples.(40) Because the difference (delta) between SaO2 and ScO2 in normal patients is ~30%, it is 
assumed that in cyanotic children the normal ScO2 ranges from 40% to 60%.(41) However, in children 
with CHD, practitioners frequently observe a wide range of ScO2 values which are attributed to the 
features  of the presenting CHD. 
In 2017, several noteworthy contributions in the field of NIRS monitoring were made, thereby enhancing 
our understanding of the use and interpretation of ScO2 values specifically as it relates to neonates and 
infants with CHD. Kussman et al. evaluated ScO2 in cyanotic (SaO2 < 90%) and acyanotic (SaO2 ≥ 90%) 
children with CHD undergoing cardiac catheterization.(42) Although the mean (±SD) ScO2 was 
statistically different between the acyanotic (74% ± 6%) and cyanotic (69% ± 6%) patients, the values in 
the cyanotic patients were within the range considered normal. The authors also estimated the cerebral 
oxygen extraction (COE) using the O2 content difference between the arterial and jugular venous bulb 
blood. In their study the authors found no difference in COE between cyanotic and acyanotic patients 
(P=.10). With cerebral oximetry monitoring the COE can be estimated noninvasively at the bedside by 
calculating the arterial-cerebral O2 saturation difference (SaO2−ScO2), or fractional O2 extraction (FOE = 
[SaO2−ScO2]/SaO2). Using the cerebral oximetry-based method the COE was significantly different 
between the two diagnostic groups (P< .001). The implications of this study are (1) a low baseline ScO2 
value in the setting of chronic hypoxemia should not merely be attributed to a lower SaO2; (2) an 
increased or increasing difference between the SaO2 and ScO2 in a cyanotic patient who is anemic or 
bleeding could lead to ScO2 levels associated with brain injury in laboratory studies (43); and (3) the 
parameters used for estimation of COE at the bedside can be misleading. 
These findings have important implications when interpreting cerebral oximetry values in children with 
CHD. For example, it has been suggested that a mixed venous oxygen saturation (SvO2) <30% represents 
the anaerobic threshold in neonates after Stage I palliation for hypoplastic left heart syndrome 
(HLHS).(44) Goal-directed therapy with SvO2 as an indicator of systemic oxygen delivery has been 
associated with excellent early survival and a low incidence of organ failure.(45) However, because SvO2 
monitoring is invasive, non-invasive ScO2 and StO2 monitoring have been suggested as substitutes for 
SvO2. This substitution is not without pitfalls and limitations. Published studies have generally shown a 
statistically significant but modest correlation between ScO2 and SvO2, but with wide limits of 
agreement.(46, 47) In postoperative pediatric cardiac surgical patients, the two variables were not 
interchangeable and ScO2 changed in the same direction as the SvO2 only 64% of the time.(48) 
In a recent study building on this concept, Rescoe et al. investigated the sensitivity of ScO2 to screen for 
compromised tissue oxygen delivery (DO2) defined as a SvO2 <30% in neonates following stage 1 
palliation for HLHS.(49) The main finding of this study was an insensitivity of cerebral oximetry in 
detecting a SvO2 <30% in the ScO2 range of clinical interest (i.e. ScO2 30-50%). When SvO2 was <30%, 
cerebral ScO2 was <30% in less than 1%, <40% in less than 1%, and <50% in 45.7% of paired ScO2 and 
SvO2 cooximetry measurements. Put another way, 54.3% of the data points with a ScO2 >50% were 
associated with a SvO2 <30% (Figure 1). This is consistent with the physiology of preservation of CBF 
with decreasing cardiac output. 
Aside from studies furthering our understanding of ScO2interpretation, technological advances in NIRS-
based tissue oxygenation monitoring are being investigated. Commercial oximeters use continuous wave 
(CW) spatially-resolved NIRS to measure blood hemoglobin-oxygen saturation in the tissue beneath the 
sensor. Because ScO2 is not a direct measure of cerebral oxygen delivery or consumption (CMRO2), 
inferences need to be made regarding cerebral oxygen balance. Frequency-domain near infrared 
spectroscopy (FD-NIRS) and diffuse correlation spectroscopy (DCS) are advanced optical technologies 
which allow for quantitative measurement of absolute cerebral oxygen saturation, oxyhemoglobin 
(HbO2), deoxyhemoglobin (HbR), total hemoglobin (HbT) from which cerebral blood volume (CBV) is 
derived, cerebral blood flow (CBF), and a calculated estimate of CMRO2.(50) 
Ferradal et al. demonstrated the feasibility of a hybrid FD-NIRS/DCS system for intraoperative 
assessment of cerebral blood flow and oxygen metabolism in neonatal cardiac surgery.(51) Cerebral 
blood flow and CMRO2 were quantified before, during, and after deep hypothermic cardiopulmonary 
bypass (CPB) in 9 neonates. The findings of a decrease in CBF and CMRO2 with a change in coupling 
during deep hypothermia are consistent with the invasive techniques in the pioneering studies by Greeley 
et al.(52, 53) This study supports the concept of FD-NIRS/DCS to monitor cerebral physiology and 
provide the potential for individual optimization of surgical management. 
Additionally, over the past decade there has been increasing recognition of the contribution of genetics, 
placental dysfunction, and direct trophic influences of abnormal cerebral perfusion and oxygenation to the 
adverse neurocognitive outcomes in children with CHD.(54, 55)  Brain abnormalities before surgery in 
neonates with severe CHD include smaller global and regional cerebral volumes, delayed maturation (by 
about one month), white matter injury (periventricular leukomalacia), and abnormal metabolism. The 
study by Kelly et al. published in 2017 adds to the growing body of evidence that abnormal circulatory 
patterns result in decreased cerebral DO2 and impaired brain growth.(56) In a comparison between 30 
newborns with mixed CHD before surgery and 30 age-matched healthy controls, cerebral DO2 was 
linearly related to cortical grey matter volume and gyrification index, with the greatest impairments 
associated with those lesions with the lowest cerebral DO2. These findings are in line with the seminal 
study by Limperopoulos et al. showing that the percentage of combined ventricular output through the 
aortic valve was independently associated with lower total brain volume in fetuses with CHD.(57) 
 
Mechanical Circulatory Support in Children: 
The prevalence of heart failure in children is steadily increasing, with a rate of 14.5-17/100,000 heart 
failure related admissions annually.(58) The most common comorbidities in these children are dilated 
cardiomyopathy, CHD , arrhythmia-induced heart failure and myocarditis. With aggressive medical care, 
the hospital length of stay for these patients (median of 19.5 days/admission) and mortality have 
continued to decrease.(59) However, there remains a subset of children with end-stage heart failure 
refractory to medical care. In those children, the expanded use of temporary mechanical circulatory 
support (MCS) (< 2 weeks) and long-term support with Ventricular Assist Devices (VAD) (>2 weeks of 
support) significantly decreased mortality and other outcome measures. The highlights and updates of 
short- and long-term MCS in 2017, especially issues pertinent to the practice of pediatric cardiac 
anesthesia are reviewed. 
The Second Annual Pediatric Interagency Registry for Mechanical Circulatory Support (PediMacs) report 
reviewed the data on VAD implants in the period 2012-2016, showing a rise in the number of centers as 
well as device options, with more than 430 devices implanted in 364 patients during the study period.(60) 
Cardiomyopathy is the most common indication for VAD placement (60% of patients) followed by CHD 
(21%) in which the majority are single-ventricle (SV) patients (48/77). The most common age of children 
supported on VAD was the 11-18 year old (48% of patients), with neonates and infants forming 20% of 
the population. VAD implantation in CHD is more challenging than other in other indications due to 
anatomical abnormalities and communications and previous heart surgeries. The VAD use and duration of 
support as a bridge-to-transplant (BTT) increases in the adolescents. The most common support is L-
VAD (80%), Bi-VAD 15% and Total Artificial Heart (Syncardia TAH, LLC, Tucson, AZ) (2%). 
Complications such as bleeding, infection and stroke are common especially with the paracorporeal 
pulsatile devices (Berlin Excor, Berlin Heart AG, Berlin, Germany) significantly more than with the 
implantable continuous flow devices including the HeartWare HVAD (HeartWare Inc., Framingham, 
MA) and the HeartMate II (St Jude Medical Inc., St Paul, MN). The majority of complications occur 
within 3 month of implantation. Mortality is higher in younger and smaller patients possibly due to the 
more frequent CHD indications and the limited availability or increased size discrepancy with continuous 
flow devices.(60)
 
Temporary Mechanical Circulatory Support: The Role of Impella
®
 in Pediatrics. 
Cardiogenic shock remains a significant cause of morbidity and mortality in children with acute heart 
failure refractory to maximized medical treatment (e.g. high dose inotropes and mechanical ventilation). 
Temporary support has been available with extracorporeal membrane oxygenators (ECMO), and with 
percutaneous continuous flow devices including the Tandem Heart (CardiacAssist Technologies, 
Pittsburgh, PA) and most recently with Impella device (Abiomed Inc., Danvers, MA). Parekh and 
colleagues reported in a retrospective review the outcomes, implant techniques, complications, and 
hemodynamic data of 10 Impella
®
 insertions at single pediatric heart center.(61) The diagnosis included 5 
post-transplant rejection or allograft vasculopathy patients, 2 with myocarditis, and one patient with 
refractory ventricular tachycardia. Impella
®
 was used as a solo support in 6 children and in 4 was used in 
addition to ECMO for left heart decompression. The device size (Impella 2.5/5.0 and CP) was chosen 
based on patient weight, vessel size and level of support required. Echocardiography was used to optimize 
device positioning. Impella
®
 support was associated with reduction in pulmonary capillary wedge 
pressures (p < 0.039) and improved end-organ perfusion evidenced by increases in the cerebral and 
somatic near infrared spectroscopy (p=0.039). Complications were reported in 8/10 implantations most 
importantly device purge failure, insertion site bleeding and limb ischemia. All patients survived to 
discharge from the intensive care unit with one late death. A similar multicenter study of Impella device 
support of the systemic circulation in pediatric patients reported a median support duration of 45 hours, 
survival of 85% at 7 days and 68% at 30 days following support. Most children experienced recovery of 
ventricular function with the temporary Impella support (41% of patients), or transition to a long term 
MCS (30%). Clearly, the use of these devices will increase both for procedural support in the 
catheterization laboratory as well as for temporary support to recovery or bridge to long-term devices.(62)
 
The support of a failing Fontan circulation is challenging. Morray et al published a multicenter, 
retrospective study of the Impella
®
 to support the systemic ventricle in a cohort of Fontan patients with 
either ventricular failure (N=8) or high-risk electrophysiology (EP) procedures (N=2).(63) The median 
duration of support was 49 hr. (2.7–264 hr.) with a hospital survival of 80% (7 weaned off, 2 transitioned 
to long-term device, and 1death). Adverse events occurred in 4 patients (hemolysis, aortic valve 
insufficiency with implant and thrombus).  These emerging evidence suggest that Impella
®
 can provide 
temporary support in pediatric patients with cardiogenic shock including SV patients as a bridge to 
recovery or long-term support. Complications rate is high but might be due to the initial experience with 
this device in pediatrics. 
Compared to a propensity-score matched cohort of children supported with ECMO as a bridge to 
transplant, patients with temporary MCS had a longer support duration (median 19 days vs 6 days, 
p<0.001) and longer overall survival before and after transplant.(64) 
Long Term Devices: Advances in Pediatric Ventricular Devices. 
Pediatric VADs implantation is following the adult trend of increased use of continuous-flow devices. 
These devices offer design simplicity, low complication rate and durability. This presents a paradigm shift 
in the type of devices used, the patient selection and the expected outcomes. In a review of the most 
important changes in VAD support in children, Adachi and colleagues highlights the findings form the 
most recent PediMacs report.(65) He outlines the emerging evidence of better outcomes with continuous 
flow implantable devices. He highlights the concern that continuous flow VADs were designed for adults 
and older children. However, its use in smaller children (< 25 kg) results in patient-device size mismatch 
worsening the outcome. The future of continuous VAD support is in miniaturized devices including the 
axial-flow implantable infant Jarvik 2015 VAD (Jarvik Heart, Inc., New York, NY) which is in its final 
stages of experimental trials prior to human implants.(66) 
One innovative approach is to “inactivate” the listing for transplant for at least 3 months after the 
continuous VAD insertion in children (grace period) with the rationale of improving the patient´s 
physiological status and increases suitability for transplantation and/or potentially recovery.(65) 
In a 10 year review (2005-2015) of the influence of transplant center procedural volume on survival 
outcome of heart transplantation for children bridged with MCS, Hsieh et al showed that patients 
supported with ECMO until transplant have inferior survivals compared to those bridged and supported 
with VAD regardless of center volumes.(67)
 
They demonstrated the significant advantage of long term 
MCS and argue for a reconsideration of the process of higher listing for children on ECMO support, 
where a bridge to VAD support for a period of time may be the better approach for improved transplant 
outcomes. 
With the increasing number of children on temporary or long-term MCS, the American Heart Association 
recently published the guidelines for cardiopulmonary resuscitation for these patients while on support.  
Peberdy et al review the challenges of diagnosis of flow and perfusion impairment in these patients 
especially in continuous flow devices, where the standard monitoring and examination become difficult to 
interpret.(68) The statement recommends to assess perfusion using standard clinical exam to rule out non-
VAD causes of arrest (e.g. hypoxia, hypoglycemia, drug overdose or stroke). Next is to investigate system 
alarms and the VAD hum to evaluate VAD function. Para-corporeal devices such as Berlin Heart EXCOR 
should be evaluated visually looking at diaphragm and valve opening/close. If the VAD is not functioning 
the device should be restarted after inspection of the power source and driveline. If the circulatory failure 
is non attributable to device failure, chest compressions should be started. Even though there is a risk of 
VAD dislodging with chest compression, the benefits outweigh the risk. The exception is with total 
artificial heart (TAH) patients, since chest compression, epinephrine and anti-arrhythmic drugs add no 
benefit and may be detrimental (Table 2). Finally the scientific statement highlights the value of early 
rescue echocardiography for the evaluation of VAD performance. Echocardiography can easily evaluate 
cardiac filling, right ventricular function, major valve dysfunction, left ventricle (LV) unloading, VAD 
cannula obstruction and aortic valve opening in systole. 
As the outcome of children with temporary and long-term MCS continues to improve, these patients will 
present to the anesthesiologist for non-cardiac surgical interventions as well as other procedures requiring 
various levels of sedation. Guidelines for the care of these patients will be necessary, as demonstrated by 
a report of 52 children on VAD support presenting for general surgery interventions. Anticoagulation 
status was not a factor in the success of the procedures. The perioperative management of these patients 
required knowledge and understanding of the device settings and a multidisciplinary team approach for an 
uneventful course.(69) 
 
Figure Legend 
Figure 1:  
Raw data for rSO2 and ScvO2 with crude linear regression line.  
Among all ScvO2 <30, there were no rSO2 values <30.   
Modified from Rescoe et al. 
(49)
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Table 1:  
Core Competencies and Milestones for the Pediatric Cardiac Anesthesia Fellowship. 
Modified from Nasr VG et al.
(10) 
Competency Milestones 
Patient Care (4)  Perioperative assessment, planning and management 
 Technical/Procedural skills 
 Understanding cardiovascular surgical procedures 
 Understanding cardiac catheter-based interventional 
procedures and electrophysiologic studies 
Medical knowledge (4)  Congenital and acquired cardiovascular anatomy, 
physiology and pathophysiology 
 Pharmacology 
 Cardiopulmonary bypass, extracorporeal circulation, and 
mechanical assist device principles 
 Understanding cardiac diagnostic procedures  
Systems-based practice (3)  Coordination of care 
 Incorporation of patient safety and quality improvement 
into clinical practice 
 Understanding of health care economics; cost awareness 
and cost-benefit analysis 
Practice-based learning and  Self-directed learning and scholarly activity 
improvement (2)  Education of pediatric cardiac care team members and 
other health care providers 
Professionalism (3)  Commitment to institution, department and colleagues 
 Receiving and giving feedback 
 Personal responsibility to maintain emotional, physical 
and mental health 
Interpersonal and 
Communication skills (2) 
 Communication with patients and families 
 Interprofessional communication and transitions of care 
 
 
  
Table 2 
Cardiopulmonary resuscitation in unresponsive children with ventricular assist devices. 
Perfusion & 
Capillary 
refill 
LVAD Echocardiography Management 
Good 
 
No alarms- 
VAD hum 
present 
Good LV unloading 
& RV function 
No valve 
insufficiency  
Treat non-LVAD causes of altered mental 
status 
 Hypoxia 
 Hypoglycemia 
 Drug overdose 
 Stroke 
Poor 
Alarms 
present- 
VAD hum 
absent 
Poor LV unloading 
RV dysfunction, 
Major valve 
insufficiency  
1. Check: 
 Driveline 
 Power source 
2. Restart VAD: 
 If perfusion improves => continue 
with ACLS protocol 
 No improvement in perfusion, MAP 
< 50 mmHg and/or EtCO2 > 20 
mmHg => start chest compressions* 
 
Abbreviations: LVAD, left ventricular assist device; LV, left ventricle; RV, right ventricle; ACLS, 
advanced cardiac life support; MAP, mean arterial pressure; EtCO2 end tidal CO2 
*TAH patient should not receive chest compression, epinephrine and/or anti-arrhythmic drugs 
 
 
